Pharmaceutical

FDA backs Astellas-Pfizer’s Padcev with Keytruda for urothelial cancer

The US FDA approved Astellas Pharma-Pfizer’s Padcev plus Merck’s (MSD) Keytruda to treat locally advanced or metastatic urothelial cancer.

Dec 18, 2023 - 10:51
FDA backs Astellas-Pfizer’s Padcev with Keytruda for urothelial cancer
The US FDA approved Astellas Pharma-Pfizer’s Padcev plus Merck’s (MSD) Keytruda to treat locally advanced or metastatic urothelial cancer.
Read the original article

Tags:

Previous Article

EMA CHMP recommends Takeda’s Hyqvia for CIDP treatment

Next Article

BMJ Investigation Shines Light on Semaglutide U.K. Marketing

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: HCA bags big first quarter as patient volumes soar

STAT+: HCA bags big first quarter as patient volumes soar

Apr 21, 2023

STAT+: HHS dispatches millions to next-generation Covid targets, including intranasal vaccine

STAT+: HHS dispatches millions to next-generation Covid...

Oct 14, 2023

Opinion: Disabled scientists are often left out of academia. The NIH can help change that

Opinion: Disabled scientists are often left out of acad...

Mar 12, 2024